Clinical trial · Observational
Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma
Open-labeled, Multicenter, Non-interventional, Prospective PRO Registry for Patients With First Line Treatment for Advanced RCC Using a Tablet-technology Based Digital Device
NCT02537743CI-TRIAL-00050888PROKidneycompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of patient reported outcomes ( PRO) regarding typical ailments in the REAL LIFE Renal Cell Carcinoma population
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Primary Outcome Measure (Patient Reported Outcomes (PRO) regarding typical ailments in the real Life RCC population)
- timeFrame
- 24 months
- description
- Patient Reported Outcomes (PRO) regarding typical ailments in the real Life RCC population
Secondary outcomes (1)
- measure
- Secondary Outcome Measures (Patient Reported Outcomes (PRO) regarding the impact of treatment on daily life)
- timeFrame
- 24 months
- description
- Patient Reported Outcomes (PRO) regarding the impact of treatment on daily life
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed renal cell carcinoma * Start of the first line systemic treatment * Ability to read and understand German * Written informed consent Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.